<DOC>
	<DOCNO>NCT00960791</DOCNO>
	<brief_summary>The purpose study evaluate absorption , distribution , metabolism excretion AZD1656 administration single oral dose 14C-labelled AZD1656 solution male Type 2 Diabetes Mellitus patient .</brief_summary>
	<brief_title>Study Assess Absorption , Distribution , Metabolism Excretion AZD1656 Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male type II diabetes patient diagnose 5 year age 35 65 year . Subjects treat metformin alone metformin one oral antidiabetic drug . Subjects FPG range 6.0 11.0 mmol/L screen HbA1c le 10 % ( HbA1c value accord international DCCT standard ) . History ischemic heart disease , stroke , transient ischemic attack symptomatic peripheral vascular disease . Renal dysfunction . Use insulin , glitazones , warfarin amiodarone within 3 month enrolment use potent CYP450 inhibitor , e.g. , ketoconazole macrolide antibiotic within 14 day administration IP .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Type II diabetes mellitus</keyword>
	<keyword>absorption</keyword>
	<keyword>distribution</keyword>
	<keyword>metabolism</keyword>
	<keyword>excretion</keyword>
	<keyword>14C-labelled</keyword>
</DOC>